Biogen Idec compound found to reduce brain lesions in MS patients

Biogen Idec has announced the results of recent research and stated a 240 mg dose three-times daily of its novel oral compound BG-12 (BG00012, dimethyl fumarate) to reduce the number of gadolinium-enhancing (Gd+) lesions in patients with multiple sclerosis.

When compared with a placebo in the phase IIb trial, the product lowered the number of lesions – which are thought to indicate ongoing inflammation in the central nervous system – in those with relapsing forms of the condition by 69 per cent.

The company also stated that an ad hoc analysis found these lesions less likely to develop into T1-hypointense lesions, which are linked to loss and breakdown of brain tissue. Following this discovery, Biogen Idec said further clinical studies are warranted.

Dr Michael Panzara, vice-president and chief executive officer at the organisation, said the use of BG-12 could provide a new way to combat brain lesions.

“Enhancing the body’s normal cellular protection pathways while reducing inflammation appears to be a unique approach to this disease,” he explained.

The results are set to be published in the Lancet this month.

According to the MS Society, about 2.5 million people across the globe are believed to suffer from the condition.